Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up

from BioCentury This Week · host BioCentury

The importance of FDA’s approval of Bristol Myers' LAG3 inhibitor Opdualag nivolumab/relatlimab for melanoma, the pharma’s disruptive marketing strategy and what’s next among checkpoints in the clinic headline the latest BioCentury This Week podcast. BioCentury's editors also discuss why there’s still a lot of excitement regarding the IL-2 cancer pipeline despite last week’s setback for Nektar Therapeutics and the paths less traveled to raising money as the downturn grinds on. This week’s podcast is sponsored by life sciences investment firm Jeito Capital. Reach us by sending a text

Episode metadata supplied by the publisher feed · Published Mar 22, 2022

Embed this episode

Attribution link and audio player

Ready to play

Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up

0:00 20:54

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioCentury This Week?

This episode is 20 minutes long.

When was this BioCentury This Week episode published?

This episode was published on March 22, 2022.

Can I download this BioCentury This Week episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!